Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00736944 · ClinicalTrials.gov registry record · Phase 2
Trial of 2 Cycles of Induction Chemo With Abraxane, Cetuximab, Cisplatin, & 5-FU for Advanced Head and Neck Cancer
A Phase 2 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT00736944 is a Phase 2 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 30 participants.
The verdict
NCT00736944, a Phase 2 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
This phase two trial will determine the tumor response rate at the primary site and at involved regional nodes to two cycles of an IC regimen of weekly Abraxane and cetuximab given in combination with cisplatin and 5-FU in patients with local regionally advanced HNSCC.
Interventions
- DRUG Cisplatin
- DRUG Cetuximab
- DRUG 5-FU
- DRUG Abraxane
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2008-12-19 |
| Est. Completion | 2020-07-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00736944
The ClinicalTrials.gov registry entry for NCT00736944 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Cisplatin is the first listed.
NCT00736944 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00736944 about?
NCT00736944 is a clinical study titled "Trial of 2 Cycles of Induction Chemo With Abraxane, Cetuximab, Cisplatin, & 5-FU for Advanced Head and Neck Cancer". This phase two trial will determine the tumor response rate at the primary site and at involved regional nodes to two cycles of an IC regimen of weekly Abraxane and cetuximab given in combination with cisplatin and 5-FU in patients with local regionally advanced HNSCC.
What is the current status of trial NCT00736944?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2008-12-19. Estimated completion is 2020-07-06.
What interventions are being tested in trial NCT00736944?
The interventions under investigation include: Cisplatin (DRUG), Cetuximab (DRUG), 5-FU (DRUG), Abraxane (DRUG).
Who is sponsoring clinical trial NCT00736944?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.